256 related articles for article (PubMed ID: 23938309)
21. A proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n-of-1) study of naftazone in Parkinson's disease.
Rascol O; Ferreira J; Nègre-Pages L; Perez-Lloret S; Lacomblez L; Galitzky M; Lemarié JC; Corvol JC; Brotchie JM; Bossi L
Fundam Clin Pharmacol; 2012 Aug; 26(4):557-64. PubMed ID: 21585523
[TBL] [Abstract][Full Text] [Related]
22. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
Deleu D; Hanssens Y; Northway MG
Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
[TBL] [Abstract][Full Text] [Related]
23. A Randomized Trial Assessing the Safety, Pharmacokinetics, and Efficacy During Morning Off of AZ-009.
Thijssen E; den Heijer J; Puibert D; Moss L; Lei M; Hasegawa D; Keum K; Mochel K; Ezzeldin Sharaf M; Alfredson T; Zeng W; van Brummelen E; Naranda T; Groeneveld GJ
Mov Disord; 2022 Apr; 37(4):790-798. PubMed ID: 35048423
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study.
García Ruiz PJ; Sesar Ignacio A; Ares Pensado B; Castro García A; Alonso Frech F; Alvarez López M; Arbelo González J; Baiges Octavio J; Burguera Hernández JA; Calopa Garriga M; Campos Blanco D; Castaño García B; Carballo Cordero M; Chacón Peña J; Espino Ibáñez A; Gorospe Onisalde A; Giménez-Roldán S; Granés Ibáñez P; Hernández Vara J; Ibáñez Alonso R; Jiménez Jiménez FJ; Krupinski J; Kulisevsky Bojarsky J; Legarda Ramírez I; Lezcano García E; Martínez-Castrillo JC; Mateo González D; Miquel Rodríguez F; Mir P; Muñoz Fargas E; Obeso Inchausti J; Olivares Romero J; Olivé Plana J; Otermin Vallejo P; Pascual Sedano B; Pérez de Colosía Rama V; Pérez López-Fraile I; Planas Comes A; Puente Periz V; Rodríguez Oroz MC; Sevillano García D; Solís Pérez P; Suárez Muñoz J; Vaamonde Gamo J; Valero Merino C; Valldeoriola Serra F; Velázquez Pérez JM; Yáñez Baña R; Zamarbide Capdepon I
Mov Disord; 2008 Jun; 23(8):1130-6. PubMed ID: 18442107
[TBL] [Abstract][Full Text] [Related]
25. [Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients].
Rambour M; Moreau C; Salleron J; Devos D; Kreisler A; Mutez E; Simonin C; Annic A; Dujardin K; Destée A; Defebvre L
Rev Neurol (Paris); 2014 Mar; 170(3):205-15. PubMed ID: 24594365
[TBL] [Abstract][Full Text] [Related]
26. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease.
Hauser RA; Olanow CW; Dzyngel B; Bilbault T; Shill H; Isaacson S; Dubow J; Agro A
Mov Disord; 2016 Sep; 31(9):1366-72. PubMed ID: 27430123
[TBL] [Abstract][Full Text] [Related]
27. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
Simpson DM; Messina J; Xie F; Hale M
Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
[TBL] [Abstract][Full Text] [Related]
28. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Jost WH; Klasser M; Reichmann H
Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
[TBL] [Abstract][Full Text] [Related]
29. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.
Stathis P; Konitsiotis S; Tagaris G; Peterson D;
Mov Disord; 2011 Feb; 26(2):264-70. PubMed ID: 21412833
[TBL] [Abstract][Full Text] [Related]
30. A double-blind study of the efficacy of apomorphine and its assessment in 'off'-periods in Parkinson's disease.
van Laar T; Jansen EN; Essink AW; Neef C; Oosterloo S; Roos RA
Clin Neurol Neurosurg; 1993 Sep; 95(3):231-5. PubMed ID: 8242966
[TBL] [Abstract][Full Text] [Related]
31. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease.
Hauser RA; Schapira AH; Rascol O; Barone P; Mizuno Y; Salin L; Haaksma M; Juhel N; Poewe W
Mov Disord; 2010 Nov; 25(15):2542-9. PubMed ID: 20669317
[TBL] [Abstract][Full Text] [Related]
32. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
[TBL] [Abstract][Full Text] [Related]
33. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
Manson AJ; Turner K; Lees AJ
Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
[TBL] [Abstract][Full Text] [Related]
34. Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating "off" episodes in advanced Parkinson disease.
LeWitt PA; Ondo WG; Van Lunen B; Bottini PB
Clin Neuropharmacol; 2009; 32(2):89-93. PubMed ID: 18978491
[TBL] [Abstract][Full Text] [Related]
35. Intermittent subcutaneous apomorphine therapy for 'off' episodes in Parkinson's disease: a 6-month open-label study.
Trosch RM; Silver D; Bottini PB
CNS Drugs; 2008; 22(6):519-27. PubMed ID: 18484793
[TBL] [Abstract][Full Text] [Related]
36. A randomized study of rotigotine dose response on 'off' time in advanced Parkinson's disease.
Nicholas AP; Borgohain R; Chaná P; Surmann E; Thompson EL; Bauer L; Whitesides J; Elmer LW;
J Parkinsons Dis; 2014; 4(3):361-73. PubMed ID: 24643203
[TBL] [Abstract][Full Text] [Related]
37. Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone.
Rascol O; Barone P; Behari M; Emre M; Giladi N; Olanow CW; Ruzicka E; Bibbiani F; Squillacote D; Patten A; Tolosa E
Clin Neuropharmacol; 2012; 35(1):15-20. PubMed ID: 22222634
[TBL] [Abstract][Full Text] [Related]
38. Continuous subcutaneous apomorphine monotherapy in Parkinson's disease.
Papuć E; Trzciniecka O; Rejdak K
Ann Agric Environ Med; 2019 Mar; 26(1):133-137. PubMed ID: 30922043
[TBL] [Abstract][Full Text] [Related]
39. Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson's disease complicated by OFF episodes: a phase 3, open-label study.
Kassubek J; Factor SA; Balaguer E; Schwarz J; Chaudhuri KR; Isaacson SH; Wu S; Denecke Muhr C; Kulisevsky J
J Neurol; 2024 Jun; 271(6):3554-3570. PubMed ID: 38546829
[TBL] [Abstract][Full Text] [Related]
40. Computational analysis of open loop handwriting movements in Parkinson's disease: a rapid method to detect dopamimetic effects.
Eichhorn TE; Gasser T; Mai N; Marquardt C; Arnold G; Schwarz J; Oertel WH
Mov Disord; 1996 May; 11(3):289-97. PubMed ID: 8723147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
